Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer

OBJECTIVES:

Primary

• To evaluate the effect of aprepitant on cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics as measured by plasma AUC in patients with breast cancer.

Secondary

• To evaluate total control of nausea and vomiting, as defined by no vomiting episodes and no use of rescue medication, 72 hours after courses 1 and 2 of chemotherapy.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive aprepitant 125 mg orally once daily on day 1 and 80 mg orally once daily on days 2 and 3. Beginning 1 hour after receiving aprepitant, patients receive an infusion of cyclophosphamide on day 1. During course 2, patients crossover and receive treatment (placebo) as in arm II.
• Arm II: Patients receive a placebo 125 mg orally once daily on day 1 and 80 mg orally once daily on days 2 and 3. Beginning 1 hour after receiving the placebo, patients will receive an infusion of cyclophosphamide infusion on day 1. During course 2, patients crossover and receive treatment (aprepitant) as in arm I.

Patients complete a diary documenting nausea and vomiting on days 1, 2, and 3 of both courses. Patients also complete The Functional Living Index-Emesis (FLIE) questionnaire documenting compliance, rescue antiemetic therapy, and any adverse effects and record them in the diary for each course. Information in the patient's diary is obtained by the coordinator via telephone on day 4 of each course.

Patients undergo blood sample collection periodically for pharmacokinetic studies via high performance liquid chromatography.

DISEASE CHARACTERISTICS:

• Diagnosis of breast cancer
• Planning to receive cyclophosphamide 600 mg/m²-1,000 mg/m² IV infusion

• No cyclophosphamide dose change between courses 1 and 2

PATIENT CHARACTERISTICS:

• Life expectancy ≥ 2 months
• ANC ≥ 1,500/μL
• Platelet count ≥ 100 x 10^9/L
• Hemoglobin ≥ 9.0 g/dL
• Serum creatinine ≤ 1.5 mg/dL
• AST/ALT ≤ 2 times upper limit of normal
• Not pregnant or nursing
• No contraindication to aprepitant

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• No concurrent medications that are CYP3A4 substrates, inhibitors, and/or inducers, with the exception of the dexamethasone contained as part of the standard antiemetic regimen